Skip to main content

Table 1 Baseline Patient and Disease Characteristics and Best Responses after Low-Dose RT

From: Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy

ID # Age Sex Histology IO Agent High-Dose RT Site High Dose RT, (Gy/fx) Low-Dose Site Low-Dose Type Mean Low-Dose (Gy/fx) Time between RT & IO Time to Response to RT, days Low-Dose Lesions, no. Low-Dose Lesion Response, %* No-Dose
Lesions, no.
No-Dose
Lesion Response, %*
1 91 M Adenocarcinoma Pembrolizumab Lung 45/15 Lung Scatter 18.92/15 0 42 1 −100% 2 8%
2 52 M Adenocarcinoma Pembrolizumab Lung 50/4 Lung Scatter 2.45/4 52 26 1 −19% 2 −30%
3 69 M SCC Ipilimumab Lung 50/4 Lung Scatter 6.49/4 32 54 3 −100% 1 −22%
4 21 F HCC Ipilimumab Lung 50/4 Lung Scatter 3.05/4 39 21 1 −65% 5 −38%
5 73 F Adenocarcinoma Ipilimumab Lung 50/4 Lung Scatter 2.47/4 27 42 1 −21% 1 −2%
6 67 F Adenocarcinoma Ipilimumab Liver 50/4 Liver Scatter 6.43/4 1 38 1 −59% 0
7 63 M Adenocarcinoma Ipilimumab Liver 50/4 Liver Scatter 9.32/4 1 35 1 −47% 1 −45%
8 60 M Adenocarcinoma Ipilimumab Liver 50/4 Lung Scatter 24.11/4 25 39 1 −63% 3 7%
9 49 F ACC Pembrolizumab Lung 50/4 Lung Scatter 12.03/4 39 38 2 −6% 1 −4%
10 53 F Adenocarcinoma Ipilimumab Lung 50/4 Lung Scatter 4.01/4 27 23 1 − 35% 2 −23%
11 44 M ACC Ipilimumab Lung 50/4 Lung Scatter 5.14/4 37 43 2 −43% 2 −33%
12 65 M CRC Ipilimumab Lung 50/4 Lung Scatter 19.43/4 29 10 2 −41% 4 44%
13 43 M RCC Ipilimumab Lung 50/4 Liver Scatter 14.4/4 1 45 1 −53% 5 −41%
14 56 M Neuroendocrine Ipilimumab Liver 50/4 Liver Scatter 15.5/4 26 153 3 −11% 3 10%
15 59 M ACC Ipilimumab Liver 50/4 Liver Scatter 21.8/4 22 12 3 −5% 3 −7%
16 74 M Adenocarcinoma Ipilimumab Lung 50/4 Abdomen Scatter 6.27/4 1 40 1 −36% 1 14%
17 62 F Adenocarcinoma Ipilimumab Lung 50/4 Lung Scatter 6.06/4 96 38 1 −42% 2 −55%
18 71 M Adenocarcinoma Pembrolizumab Lung 50/4 Lung Scatter 12.97/4 105 81 1 −100% 1 53%
19 49 M DLBCL Pembrolizumab Inguinal 50/20 Inguinal Scatter 4.74/20 31 70 1 −100% 1 −4%
20 53 M Adenocarcinoma Pembrolizumab Lung 45/15 Lung Scatter 12.20/15 74 114 1 −42% 0
21 53 M SCC Pembrolizumab Lung 50/4 Abdomen Intentional 8/4 39 109 1 −25% 1 −56%
22 65 F Adenocarcinoma Pembrolizumab Lung 52.5/15 Lung Intentional 7.5/5 27 119 2 −67% 1 64%
23 69 M MCC Atezolizumab Adrenal 70/10 Inguinal Intentional 6/6 27 19 2 −32% 0
24 80 M SCC Nivolizumab Lung 52.5/15 Lung Intentional 6/6 26 67 1 −11% 0
25 56 F Melanoma Ipilimumab Spleen 25/5 Liver Intentional 7.5/5 1 29 2 −7% 2 22%
26 69 F Adenocarcinoma Atezolizumab Liver 60/10 Abdomen Intentional 8/4 1 39 1 −7% 1 0%
  1. Abbreviations: RT radiation, IO immunotherapy, SCC squamous cell carcinoma, HCC hepatocellular carcinoma, ACC adrenal cortical carcinoma, RCC renal cell carcinoma, DLBCL diffuse large B cell lymphoma, MCC Merkel Cell Carcinoma